Timothy L. Clenney, MD, MPH

In patients with cancer and venous thromboembolism, low-molecular-weight heparin effectively reduces symptomatic recurrent venous thromboembolism (VTE) more effectively than warfarin. Although cost and logistical considerations should be considered, this study demonstrates that the use of low-molecular-weight heparin is an effective approach for the prevention of recurrent VTE in cancer patients.

In patients with cancer and venous thromboembolism, low-molecular-weight heparin effectively reduces symptomatic recurrent venous thromboembolism (VTE) more effectively than warfarin. Although cost and logistical considerations should be considered, this study demonstrates that the use of low-molecular-weight heparin is an effective approach for the prevention of recurrent VTE in cancer patients.

In patients with cancer and venous thromboembolism, low-molecular-weight heparin effectively reduces symptomatic recurrent venous thromboembolism (VTE) more effectively than warfarin. Although cost and logistical considerations should be considered, this study demonstrates that the use of low-molecular-weight heparin is an effective approach for the prevention of recurrent VTE in cancer patients.